JoVE Journal
Chemistry
Chemistry
JoVE 비디오를 활용하시려면 도서관을 통한 기관 구독이 필요합니다.
챕터
요약
This protocol describes the synthesis and characterization of a trans-cyclooctene (TCO)-modified antibody and a 177Lu-labeled tetrazine (Tz) radioligand for pretargeted radioimmunotherapy (PRIT). In addition, it details the use of these two constructs for in vivo biodistribution and longitudinal therapy studies in a murine model of colorectal cancer.